<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440309</url>
  </required_header>
  <id_info>
    <org_study_id>2008BAI59B03/2011AA020119</org_study_id>
    <nct_id>NCT01440309</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis</brief_title>
  <acronym>MSCsTreatPBC</acronym>
  <official_title>Phase I Clinical Trial, Randomized, Controlled, to Evaluate the Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells From Bone Marrow for Patients With Refractory Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Chunhua Zhao, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety and efficacy of intravenous administration of
      bone marrow derived mesenchymal stem cells for patients with refractory primary biliary
      cirrhosis (PBC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary biliary cirrhosis (PBC) is an organ-specific inflammatory disease and characterized
      by immune mediated destruction of intrahepatic bile ducts, then lead to liver cirrhosis and
      eventually failure.Currently, ursodeoxycholic acid (UDCA) is the only drug approved by the
      Food and Drug Administration (FDA). Novel treatment is urgently needed for patients who have
      an incomplete response to UDCA. Mesenchymal stem cells (MSC) represent a promising tool for
      cell-based therapies of autoimmune diseases. To explore the therapeutic effect of MSCs for
      PBC, the investigators plan to conduct an open-label, randomized clinical trial. Patients
      with PBC will be enrolled and randomly divided into two groups which will receive MSCs and
      UDCA respectively. The investigators will evaluate the efficacy and safety of MSCs for PBC by
      comparison of symptom improvement, survival rate and side effects in the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum level of alkaline phosphatase</measure>
    <time_frame>24 months after MSCs administration</time_frame>
    <description>Serum level of alkaline phosphatase will be measured at entry, 1 months，3 months, 6 months and 24 months after therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>histological changes in liver biopsies</measure>
    <time_frame>6 months after therapy</time_frame>
    <description>Liver biopsy of each patient will be taken before entry into therapeutic trials and at 6 months after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of TNF-alpha</measure>
    <time_frame>6 months after therapy</time_frame>
    <description>serum levels of TNF-alpha will be assessed before entry into therapeutic trials and at 6 months after therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in fatigue</measure>
    <time_frame>6 months after theraphy</time_frame>
    <description>changes in fatigue will be evaluated before test (baseline), 1 month,3 months and 6 months after theraphy by PBC-40 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of cirrhosis and its complications</measure>
    <time_frame>24 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Interleukin</measure>
    <time_frame>6 months after therapy</time_frame>
    <description>serum levels of Interleukin will be assessed before entry into therapeutic trials and at 6 months after therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in pruritus severity</measure>
    <time_frame>6 months after therapy</time_frame>
    <description>changes in pruritus severity will be evaluated before test (baseline), 1 month,3 months and 6 months after theraphy by VAS score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>allogenic mesenchymal stem cells (MSCs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have primary biliary cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ursodeoxycholic acid (UDCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have primary biliary cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological: mesenchymal stem cell</intervention_name>
    <description>Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition</description>
    <arm_group_label>allogenic mesenchymal stem cells (MSCs)</arm_group_label>
    <other_name>regenerative medicine:MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodeoxycholic acid</intervention_name>
    <description>13-15 mg/kg/day, to the end of the study</description>
    <arm_group_label>ursodeoxycholic acid (UDCA)</arm_group_label>
    <other_name>UDCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  There must be at least two of the following: a concentration in serum of AMAs at
             titres of 1:40 or higher; an unexplained rise in the amount of alkaline phosphatase of
             at least 1•5 times the upper limit of normal for more than 24 weeks; and compatible
             liver histological findings, specifically non-suppurative cholangitis and interlobular
             bile duct injury.

          -  Incomplete response to UDCA at 13-15 mg/kg/day, Criteria for the group of complete
             responders is including: concentrations of alkaline phosphatase less than three times
             the upper limit of normal, aspartate aminotransferase less than twice the upper limit
             of normal, and bilirubin less than 17 μmol/L;and normalisation of abnormal
             concentrations of bilirubin, albumin, or both.

          -  Liver pathological staging in 2 or3, Histological staging is based on Ludwig's and
             Scheuer's classifications

        Exclusion Criteria:

          -  Patients are receiving any other investigational agents within 4 weeks of study entry

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (defined as invasive fungal infection and progressive CMV viremia),
             symptomatic congestive heart failure (NYH class III and IV), unstable angina pectoris,
             or cardiac arrhythmia

          -  In pregnancy or lactation

          -  Psychiatric illness or mental deficiency making compliance with treatment or informed
             consent impossible

          -  HCVpositive ，HBSAg positive or with other liver diseases

          -  Combined with other autoimmune disease

          -  Expected survival time is less than one year

          -  Decompensation of liver function（Child B or C）

          -  Have a history of allergy or Allergic constitution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Chunhua Zhao, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fengchun Zhang, MD</last_name>
    <phone>0086-10-65296891</phone>
    <email>zhangfccra@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunjiao Yang, MD</last_name>
    <phone>0086-10-65295047</phone>
    <email>yangyunjiao81@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengchun Zhang, MD</last_name>
      <email>zhangfccra@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sun Z, Han Q, Zhu Y, Li Z, Chen B, Liao L, Bian C, Li J, Shao C, Zhao RC. NANOG has a role in mesenchymal stem cells' immunomodulatory effect. Stem Cells Dev. 2011 Sep;20(9):1521-8. doi: 10.1089/scd.2010.0366. Epub 2011 Feb 26.</citation>
    <PMID>21235326</PMID>
  </reference>
  <reference>
    <citation>Shi D, Liao L, Zhang B, Liu R, Dou X, Li J, Zhu X, Yu L, Chen D, Zhao RC. Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-κB signaling. Exp Hematol. 2011 Feb;39(2):214-224.e1. doi: 10.1016/j.exphem.2010.10.009. Epub 2010 Nov 13.</citation>
    <PMID>21078360</PMID>
  </reference>
  <reference>
    <citation>Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, Zhu X, Lu C, Liang W, Liao L, Zenke M, Zhao RC. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009 Jan 1;113(1):46-57. doi: 10.1182/blood-2008-04-154138. Epub 2008 Oct 2.</citation>
    <PMID>18832657</PMID>
  </reference>
  <reference>
    <citation>Liao L, Zhao RC. An overview of stem cell-based clinical trials in China. Stem Cells Dev. 2008 Aug;17(4):613-8. doi: 10.1089/scd.2008.0183. Review.</citation>
    <PMID>18673001</PMID>
  </reference>
  <reference>
    <citation>Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation. 2004 Jul 15;78(1):83-8.</citation>
    <PMID>15257043</PMID>
  </reference>
  <reference>
    <citation>Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L, Zhao RC. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res. 2009 Dec;39(12):1219-28. doi: 10.1111/j.1872-034X.2009.00564.x. Epub 2009 Sep 25.</citation>
    <PMID>19788697</PMID>
  </reference>
  <reference>
    <citation>Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M, Li J, Li B, You S, Shi Y, Zhao RC. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007 Oct;16(5):719-31.</citation>
    <PMID>17999594</PMID>
  </reference>
  <reference>
    <citation>Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 2005 Jul;24(7):458-63.</citation>
    <PMID>16008514</PMID>
  </reference>
  <reference>
    <citation>Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC. Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol. 2004 Sep;32(9):861-7.</citation>
    <PMID>15345288</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004 Jun;13(3):263-71.</citation>
    <PMID>15186722</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Robert Chunhua Zhao, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD，Professor of medicine</investigator_title>
  </responsible_party>
  <keyword>biliary cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

